2. >>Leadership
  3. >>C-Suite Speaks

With A Transformational Year Underway, Insmed Ramps Up

 
• By David Wild

With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.

Spaceship blueprints
'I feel like we're building a rocket that's about to take off.' • Source: Shutterstock

Will Lewis, CEO of New Jersey-based Insmed Incorporated, believes this year will be transformational for the company, not least because it has several parallel late-stage clinical programs reaching maturation.

“We’re stacking a lot of events on top of each other that are quite significant for the company,” Lewis told In Vivo at the 2024 J.P. Morgan Healthcare Conference

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

More from Leadership